Alpha HPA Limited Overview
Alpha HPA is an Australian specialty advanced-materials manufacturer commercialising an exclusively licensed and company-consolidated solvent-extraction purification process, branded Smart SX Technology, which it describes as the first application of solvent extraction to aluminium purification. Rather than starting from energy-intensive aluminium metal, the process leaches a common aluminium hydroxide feedstock in nitric acid and refines it through ion exchange and solvent extraction into ultra-high-purity (4N5 to 5N) aluminas, aluminium hydroxide (ATH), aluminium nitrate and synthetic sapphire. A ~380 tpa Stage One plant has run continuously in Gladstone since late 2022 and is roughly three times oversubscribed; a ~10,000 tpa Stage Two plant — positioned as the world's largest single-site high-purity aluminium materials facility — is under construction for first production in late 2027. Its commercial thesis has pivoted decisively toward AI-driven semiconductor demand (thermal fillers, CMP slurries, fab ceramics), with sovereign-capital backing from NAIF, EFA, NRFC and QIC.
What the company does
Alpha HPA manufactures ultra-high-purity aluminium materials. Its company self-description in the FY2026 Annual Report characterises it as an Australian advanced-materials company that exclusively commercialises a scientific process for making ultra-high-purity aluminium materials for demanding high-technology industries, using Smart SX Technology to produce a growing portfolio of ultra-high-purity alumina, aluminium nitrate, aluminium hydroxide and synthetic sapphire material. The company states that the process uses a readily available industrial feedstock instead of aluminium metal, recycles almost all reagents and process streams, and produces materially lower emissions and waste than incumbent routes (FY2026 Annual Report, "About us").
The chemistry, as summarised by the NRFC in its January 2026 investment release, involves nitric-acid leaching of high-grade aluminium hydroxide, followed by ion exchange and solvent extraction to recover and separate aluminium nitrate at very high purity, which is then converted into an intermediate precursor and finally into HPA at lower temperatures than conventional processes. The adjacency to Orica's Yarwun plant creates a closed loop: Orica supplies reagents (principally nitric acid) and takes back by-products for reuse (NRFC release, January 2026).
Business model and revenue model
| Revenue type | Current status (FY2026) | Commentary |
|---|---|---|
| Product sales — high-purity aluminas, ATH, Al-nitrate, nano-dispersions | Primary revenue source; A$747,150 total statutory sales revenue FY2026 including sapphire | Sold per kg in USD (weighted average ~US$25.86/kg ex-sapphire in the June 2026 quarter) |
| Product sales — synthetic sapphire (Alpha Sapphire) | Small; sapphire sales up 425% year-on-year in FY2026 from a very low base | Boules and 200 mm wafers to an optics customer in Hong Kong/China and a semiconductor customer in Austria |
| Services / subscription | — | — |
| Licensing | None outbound; Alpha is itself a licensee/owner of consolidated process IP | — |
| Other income | A$2.90 million FY2026 (A$3.11 million FY2025), principally grant income recognition and R&D incentives | Not operating revenue |
| Finance income | A$3.51 million FY2026 (A$7.17 million FY2025) on cash balances | Declines as cash is deployed into construction |
The business model is that of a vertically integrated specialty-chemicals manufacturer selling technically qualified, customer-specific materials under business-to-business contracts. The company's risk disclosures note that pricing for its products is set through technically qualified B2B negotiation that is opaque and end-user specific — i.e., there is no exchange-traded benchmark price (FY2026 Annual Report, Governance and Risk table).
Effectively 100% of operating revenue is product revenue. The company is in a transitional "qualification sales" model: Stage One volumes are sold in kilogram-to-tonne lots to over 100 end-users for qualification and early commercial supply, with the explicit aim of converting non-binding Letters of Intent (LOIs) into binding offtake contracts for Stage Two.
Value-chain position
Alpha sits in the midstream of the aluminium-materials value chain: downstream of bulk alumina/aluminium hydroxide producers (its feedstock), upstream of materials formulators (spherical thermal-filler makers, CMP slurry formulators, technical-ceramics manufacturers, battery cathode/separator coaters, sapphire growers) and two or three steps removed from end OEMs (memory and logic chipmakers, AI accelerator packagers, battery cell makers, LED makers, luxury watch brands). Through Alpha Sapphire it also integrates one step further downstream into crystal growth.
Customer types and end-markets
| End-market | Application | Alpha differentiation claimed (company disclosure) |
|---|---|---|
| Semiconductors — thermal management | Spherical alumina thermal fillers and thermal interface materials (TIM) for AI processors and HBM packaging | Believed to be the only manufacturer globally producing ultra-low-alpha HPA and ATH with uranium and thorium below 1 ppb |
| Semiconductors — CMP | Nano-alumina slurries for hard-to-polish substrates (hard-carbon masks for HBM/DRAM, SiC wafers, alumina dielectric, tungsten and copper layers); 5N Al-nitrate as slurry additive | Very low alkali impurities (Na, K, Li) and unique particle morphology |
| Semiconductors — fine ceramics / fab tools | Electrostatic chucks, chamber components, thermal-spray coatings, interposers, thermal base plates | Ultra-low-alpha 4N+ alumina with high sintering density (>3.9 g/cm³) |
| Direct Lithium Extraction (DLE) | Amorphous ATH as precursor for next-generation sorbents | Commercial-scale production of amorphous ATH |
| Lithium-ion batteries | Al-nitrate for battery coatings; cathode doping/coating | First to demonstrate commercial-scale 5N aluminium nitrate (company claim) |
| Pharmaceuticals | Gamma-phase alumina; bio-ceramics and dental | Regular low-volume, high-value sales to a South Korean pharmaceutical end-user |
| Synthetic sapphire / LED / optics | HPA tablets (Ultra TAB) as crystal-growth feedstock; own sapphire boules and wafers | "Low-carbon" sapphire for Swiss watch market; 200 mm C-plane wafers for GaN-on-sapphire |
| Catalysts | High-purity ATH | Qualified for up to 180 tpa; first sales in FY2026 |
| Specialty coatings / aerospace | Al-nitrate for high-temperature coatings | First commercial shipment post-30 June 2026 to a European aerospace coatings maker |
| Water treatment | Al-nitrate for PFAS sorbents | US research collaboration; seeking commercial partners |
The FY2026 Annual Report identifies five priority application areas where management believes it has clear technical differentiation, plus several niche sectors:
Independent characterisation
Alpha HPA should be understood as a single-asset, single-technology industrial scale-up story whose investment case has migrated. At the time of the March 2020 Definitive Feasibility Study (DFS) and the May 2024 updated DFS, the dominant narrative was lithium-ion battery separator coatings and LED sapphire. By FY2026 the commercial pipeline is dominated by AI semiconductor supply chains, which (a) carry higher unit values and more stringent qualification barriers, and (b) value Alpha's ultra-low-alpha (U/Th <1 ppb) capability, which is a genuinely differentiated attribute if sustained at scale. Management itself acknowledges that the physical product slate is broadly unchanged from the DFS while the end-markets have shifted materially (FY2026 Annual Report, "Looking ahead"). The key unproven elements are (i) Stage Two execution and ramp-up at 25–30x Stage One scale, (ii) conversion of >12,000 tpa of non-binding LOIs into binding, priced offtake, and (iii) achieved pricing versus DFS assumptions.
Strategy
Stated strategy (themes from the FY2026 Annual Report)
Management frames the strategy around five themes, paraphrased: (1) transition from technology developer supplying qualification volumes to a scaled advanced-materials manufacturer; (2) concentrate commercial effort where Smart SX confers a clear technological edge — purity, ultra-low alpha emission, manufacturing flexibility and commercial-scale supply; (3) prioritise the AI/semiconductor supply chain (thermal management, CMP, fab ceramics) while retaining battery, pharmaceutical, catalyst and sapphire options; (4) position Australia as a manufacturer, not merely a supplier, of critical-mineral-derived advanced materials, aligned with government sovereign-capability policy; and (5) prepare for growth beyond Stage Two through Stage Three concept studies. The corporate vision and mission emphasise innovation for people and planet and high-performance materials delivered with quality, agility and care.
Strategic initiatives — last 24 months
| Initiative | Date | Description | Target / KPI | Status |
|---|---|---|---|---|
| Stage Two HPA First construction | Ongoing since 2024 | ~10,000 tpa plant; 86 procurement packages | First production late 2027; budget A$699.2m | 75 of 86 packages awarded; 607,000 safe construction hours in FY2026; on budget/schedule vs Jan 2026 re-baseline |
| Stage Two re-baseline | Jan 2026 | Capex reset from A$553m to A$699.2m (+26%); completion late 2027–early 2028 | Hold budget and schedule | Holding as at July 2026 |
| Stage One optimisation and expansion | FY2026 | Nano mill, jet mill (>200 kg/day added), ATH debottlenecking, spray drying, ICP-OES lab | ATH from 490 to >1,400 kg/week; Al-nitrate 900 to ~1,200 kg/day; tablets ~300 kg/week; complete Oct 2026 | Largely installed; completion targeted October 2026 |
| CMP nano-slurry commercialisation | FY2025–FY2027 | In-house nano-alumina dispersion | Commercial supply FY2027 | First commercial orders; 11 formulators sampled |
| Semiconductor supply-chain entry | FY2026 | Qualification with Japanese/Korean filler makers and US equipment makers | Convert LOIs to contracts | "Formal entry" claimed; contracts in advanced negotiation |
| Lithium-ion battery LOI | FY2026 | Up to 5,000 tpa non-binding LOI with a Tier-1 battery customer | Delivery schedule aligned to Stage Two | Negotiating delivery schedule |
| Stage Three concept studies | FY2026– | Expansion beyond HPA First Facility | Demand model >50,000 tpa by 2030 | Concept phase |
| Funding stack completion | 2024–2026 | A$400m NAIF/EFA; A$225m equity; A$30m QIC; MMI-C and Qld IPP grants | Financial Close; first draw | First draw targeted Q4 CY2026 |
| HSE system upgrade | FY2026 | Evotix Assure HSE system expansion; critical-risk review; MHF safety case | Zero recordable injuries | Achieved at Gladstone; one LTI at Brisbane PDC |
| Cyber maturity | FY2026 | Gap assessment against SMB1001:2026 Gold; foreign-interference training | Certification | In progress |
ESG commitments
HPA First is designed to operate on 100% renewable electricity; the NRFC cites roughly 70% lower emissions than traditional HPA manufacturing routes (NRFC CEO quoted in Grafa). Near-zero-waste reagent recycling with Orica. A 2026 Sustainability Report is referenced in the Annual Report (climate risk strategy).
Medium-term targets / guidance
Alpha does not issue revenue or earnings guidance. Operational targets disclosed: Stage One upgrades complete October 2026; spray-drying capacity doubled by December 2026; NAIF/EFA first draw Q4 CY2026; major procurement complete by Q1 2027; Stage Two first production late 2027; Al-nitrate supply to US Tier-1 CMP formulator from late CY2026; catalyst orders to multi-tonne levels in Q1 CY2027.
Products & Services
All products are produced from the same Smart SX aluminium-nitrate intermediate. Purity designations: 4N5 = 99.995%; 5N = 99.999%.
HPA First platform
| Product (brand) | Chemistry / phase | Key specifications & capabilities (company disclosure) | Target customers / applications | Status / latest development | Pricing |
|---|---|---|---|---|---|
| Ultra AAP™ | Ultra-high-purity alpha-phase alumina powder (Al₂O₃), 4N5+ | Low U/Th (<1 ppb) for low-alpha emission | Thermal fillers, LED, CMP, battery cathode doping, technical ceramics | In Stage One production; Stage Two base case 3,200 tpa alpha-phase alumina | Not disclosed; June 2026 quarter blended ~US$25.86/kg ex-sapphire |
| Ultra AAP-X™ | Alpha-phase alumina powder, enhanced grade | Tailored morphology | Thermal management, fine ceramics, pharmaceutical | Production / qualification | — |
| Ultra AAP-DP™ | High-sintering alpha-phase alumina powder | +4N5, sintered density >3.9 g/cm³ | Semiconductor ceramic tools (electrostatic chucks, hold-down rings, lifting arms), interposers, base plates | Recently developed; second-round qualification with Japanese/Korean thermal-spray users; supplier onboarding with two US Tier-1 equipment makers | — |
| Ultra AAP-D™ | Alpha alumina nano-dispersion (slurry) | 4N5+ nano-particles with novel crystallinity; strong removal rates on hard-to-polish layers | CMP slurry formulators (HBM/DRAM hard-carbon masks, SiC wafers, dielectric, W and Cu layers) | Final-generation samples sent to 11 formulators; first commercial orders (EU end-user); in-house nano-milling commissioned mid-2026; commercial supply expected FY2027 | — |
| Ultra GAP™ | Gamma-phase alumina powder | 4N5+ | Thermal fillers, CMP, Li-ion cathode doping/coating, catalysts | Stage Two base case 2,000 tpa gamma alumina | — |
| Ultra GAP-X™ | Gamma-phase alumina, enhanced grade | Customer-specific | Thermal management; pharmaceutical (S. Korea) | Open orders >11 tonnes from Korean and Japanese semiconductor customers at July 2026 | — |
| Ultra ATH™ | Ultra-high-purity aluminium tri-hydroxide, Al(OH)₃ | 4N5+; amorphous variant for DLE | Thermal fillers, DLE sorbent precursors, cathode dopants, catalysts, pharmaceutical | Production rising from ~490 kg/week to >1,400 kg/week after Stage One upgrades; Stage Two base 1,700 tpa (upside 2,000 tpa) | — |
| Ultra ALN™ | Aluminium nitrate nonahydrate crystal, Al(NO₃)₃·9H₂O, 5N | Commercial-scale 5N | CMP slurry additive, battery coatings, solid-state electrolytes, catalysts, thermal-spray coatings, micro-LED phosphors, aerospace coatings, PFAS sorbents | Commercial terms accepted with a US Tier-1 CMP slurry formulator (supply from late CY2026); Stage One output rising from 900 to ~1,200 kg/day; Stage Two base 3,500 tpa (upside 5,000 tpa) | — |
| Nano-alumina powder (Ultra NAP) | 4N5+ nano Al₂O₃ powder | — | CMP, cathode coating, high-density sintering | Stage Two base case 30 tpa | — |
| Ultra TAB™ | Sintered HPA tablets / pucks | 5N | Synthetic sapphire growers (Kyropoulos/other methods), optics | Qualified with a sapphire optics end-user (Sep 2024 quarter); ~300 kg/week from Stage One inventory | — |
| Pseudoboehmite / amorphous variants | Alumina hydrates | High dispersibility | Semiconductor and research customers | Sample/research orders (US) | — |
Alpha Sapphire platform
| Product | Description | Customer | Status |
|---|---|---|---|
| Synthetic sapphire boules | Grown from Alpha's own HPA in two next-generation growth units (Ebner/Fametec technology) | Primary optics customer (Hong Kong/China) supplying premium Swiss watchmakers; positioned as "low-carbon" sapphire | Ongoing sales; quality program reduced bubbles, cloud zones, low-angle grain defects; eliminated molybdenum contamination |
| 200 mm C-plane sapphire wafers | Wide-format wafers | Austrian semiconductor customer qualifying GaN-on-sapphire power/RF devices | Additional orders received in FY2026 |
Product mix at Stage Two (base vs upside)
| Product (tpa) | May 2024 DFS | Upside scenario (Jul 2026) |
|---|---|---|
| 5N aluminium nitrate | 3,500 | 5,000 |
| 4N5+ alpha-phase alumina | 3,200 | 3,200 |
| 4N5+ gamma-phase alumina | 2,000 | 2,000 |
| 4N5+ ATH | 1,700 | 2,000 |
| 4N5+ nano-alumina | 30 | 30 |
| Total | 10,430 | 12,230 |
Source: June 2026 Quarterly Activities Report. The upside scenario assumes a ~5% increase in aluminium nitrate production to service additional Al-nitrate and ATH sales, based on Stage One "as-built" performance.
Financial Narrative
Income statement
Source: FY2026 Remuneration Report, "Consequences of performance on shareholder wealth".
Source: FY2026 Annual Report, Consolidated Statement of Profit or Loss. EBITDA is analyst-derived.
Gross, operating, EBITDA and net margins are not meaningful: operating costs are roughly 60x sales revenue. Revenue CAGR is not computable on a like-for-like five-year basis from retrieved data; Stage One sales grew from A$56k (FY2024) to A$556k (FY2026), a two-year CAGR of approximately 215% (derived).
Commentary on trends and drivers. Losses have widened every year for five years — from A$7.4 million in FY2022 to A$42.7 million in FY2026 — tracking the build-out of an operating organisation (employee expenses up 25% to A$16.1 million in FY2026), the depreciation of Stage One (D&A up 64% to A$5.4 million as Stage One upgrades and the Brisbane centre were added), and non-cash share-based payments (A$5.1 million). The critical inflection in FY2026 was the halving of finance income (A$7.2 million to A$3.5 million) as cash was spent on Stage Two, despite the January 2026 raise. Revenue more than doubled but remains immaterial. Importantly, Stage Two construction costs are capitalised to property, plant and equipment, so the income statement understates the cash burn; the true economic picture is in the cash-flow statement.
Balance sheet
Source: FY2026 Annual Report, Consolidated Statement of Financial Position. Total debt and net cash are analyst-derived. There is no bank debt drawn: the A$400 million NAIF/EFA facilities had not reached Financial Close at 30 June 2026 and the June 2026 Appendix 4C shows loan facilities of nil, with only the A$30 million QIC "other" facility fully drawn.
Interim data point (Half-Year Report, 31 December 2025): cash A$45.1 million, total assets A$305.3 million, total equity A$205.8 million — illustrating how close to the funding edge the company ran ahead of the January 2026 placement (cash had fallen to ~A$39 million by 22 January 2026 per the placement announcement).
Cash flow
Sources: FY2026 — June 2026 quarter Appendix 4C (12-month year-to-date column). FY2025 operating cash flow — Macquarie Research flashnote, 29 July 2025.
Quarterly run-rate (FY2026): operating outflows of A$11.4 million (March quarter) and A$11.3 million (June quarter); capex of A$47.9 million (March quarter) and A$45.8 million (June quarter). On these run-rates the company is spending roughly A$57–60 million per quarter in total.
Ratios
Company-reported ROCE (loss ÷ (total assets − current liabilities)) for the five years: FY2022 -15%, FY2023 -28%, FY2024 -10%, FY2025 -14%, FY2026 -10% (FY2026 Remuneration Report).
ROIC and cash conversion cycle are not meaningful for a pre-production entity. ROE FY2025 uses opening equity of A$247.2 million (1 July 2024) from the Statement of Changes in Equity.
Commentary. The balance sheet transformed in FY2026: total assets rose 82% to A$514.9 million and PP&E more than doubled to A$292.5 million as Stage Two capital was deployed. Equity nearly doubled to A$411.1 million on the A$225 million placement plus A$6.8 million SPP. The company enters FY2027 with ~A$167 million of liquid funds and no drawn senior debt. The forward funding equation is the decisive issue: against a re-baselined A$699.2 million Stage Two budget, the company has stated that total available funding lines including the A$400 million government debt facility (subject to conditions precedent), undisbursed grants and the placement total roughly A$704 million (InvestSMART summary of the January 2026 announcement). That implies a thin margin over budget, with the A$80 million cost-overrun facility as part of the stack. The single most important monitorable is therefore Financial Close and first draw of the NAIF/EFA facilities, now targeted for Q4 CY2026.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Platform Details
| Platform | Contents | Products / services | Status |
|---|---|---|---|
HPA First Project (Stage One and Stage Two) | Gladstone HPA First Facility; Brisbane Product Development Centre | Ultra AAP / AAP-X / AAP-DP / AAP-D (alpha alumina), Ultra GAP / GAP-X (gamma alumina), Ultra ATH, Ultra ALN (Al-nitrate), nano-alumina, Ultra TAB (tablets) | Stage One operating (~380 tpa); Stage Two under construction |
Alpha Sapphire | Two "Phase A" next-generation crystal growth units | Sapphire boules, 200 mm C-plane wafers | Qualification/small-scale sales; commercial-scale FID not yet taken |
Revenue by Segment
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Stage One sales revenue (AUD K) | 56 | 323 | 556 |
Total statutory sales revenue (AUD K) | — | 318 | 747 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansGrowth metric
| Growth metric | FY2025 | FY2026 |
|---|---|---|
Stage One sales growth YoY (%) | 476 | 72 |
Total statutory sales growth YoY (%) | — | 135.3 |
Key Financials
| Metric (AUD Mn) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Net loss attributable to owners | -7.36 | -15.68 | -24.98 | -32.56 | -42.66 |
Income Statement and Per-Share Data
| Metric (AUD Mn) | FY2025 | FY2026 |
|---|---|---|
Sales revenue | 0.318 | 0.747 |
Other income | 3.107 | 2.904 |
Changes in inventories (expense) | -3.620 | -1.996 |
Raw materials and consumables | -0.366 | -0.931 |
Employee expenses | -12.912 | -16.142 |
Purchased services | -12.059 | -10.990 |
Depreciation and amortisation | -3.326 | -5.444 |
Repairs and maintenance | -2.160 | -1.658 |
Share-based payments | -4.273 | -5.053 |
Other expenses | -5.153 | -7.162 |
Unrealised gain/(loss) on investments | 1.210 | -0.032 |
Loss before net finance income (operating result) | -39.234 | -45.757 |
Finance income | 7.166 | 3.514 |
Finance expense | -0.487 | -0.414 |
Loss before income tax | -32.555 | -42.657 |
Income tax expense | 0 | 0 |
Net loss | -32.555 | -42.657 |
EBITDA (derived: operating result + D&A) | -35.908 | -40.313 |
EPS basic and diluted (A$ cents) | -2.87 | -3.42 |
Dividends per share (A$ cents) | 0 | 0 |
Margin / growth metric
| Margin / growth metric | FY2025 | FY2026 |
|---|---|---|
Sales revenue growth YoY (%) | — | 135.3 |
Net loss growth YoY (%) | 30.3 | 31.0 |
Balance Sheet
| Metric (AUD Mn) | FY2025 | FY2026 |
|---|---|---|
Total assets | 283.371 | 514.921 |
Cash and cash equivalents | 102.036 | 113.278 |
Term deposits (current + non-current) | 5.255 | 53.896 |
Total liquid funds (cash + term deposits) | 107.291 | 167.174 |
Property, plant and equipment | 124.706 | 292.460 |
Intangible assets (no goodwill) | 3.532 | 3.267 |
Trade and other receivables (current + non-current) | 25.261 | 15.688 |
Prepayments | 13.914 | 26.319 |
Inventory | 4.336 | 4.451 |
Total current assets | 134.297 | 201.729 |
Total current liabilities | 50.566 | 59.235 |
Working capital | 83.731 | 142.493 |
Other financial liabilities (QIC royalty instrument; FY2025 Sales Support Production Facility) | 3.534 | 25.919 |
Lease liabilities (current + non-current) | 0.882 | 2.355 |
Total debt-like liabilities | 4.416 | 28.274 |
Of which short-term | 4.083 | 1.173 |
Of which long-term | 0.332 | 27.101 |
Net cash (liquid funds less debt-like liabilities) | 102.875 | 138.900 |
Deferred grant recognition (current + non-current) | 37.218 | 23.857 |
Total liabilities | 64.496 | 103.834 |
Total equity | 218.876 | 411.088 |
Issued capital | 352.718 | 580.407 |
Accumulated losses | -137.875 | -180.531 |
Cash Flow
| Metric (AUD Mn) | FY2025 | FY2026 |
|---|---|---|
Net operating cash flow | -26.5 | -40.564 |
Payments for property, plant and equipment (capex) | — | -162.119 |
Free cash flow (OCF less capex) | — | -202.683 |
Government grants received (investing) | — | 10.912 |
Proceeds from equity issues | — | 231.873 |
Equity issue costs | — | -8.105 |
QIC royalty investment (net) | — | 27.0 |
Dividends paid | 0 | 0 |
Share buybacks | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2025 | FY2026 |
|---|---|---|
Return on equity (%) — on average equity | -14.0 | -13.5 |
Return on assets (%) — on average assets | — | -10.7 |
Return on capital employed (%) — company-reported | -14 | -10 |
Current ratio (x) | 2.66 | 3.41 |
Debt-like liabilities / equity (x) | 0.020 | 0.069 |
Net debt / EBITDA
| Net debt / EBITDA | n/m (net cash) | n/m (net cash) |
|---|---|---|
Interest coverage | n/m | n/m |
Asset turnover (sales / average assets) (x) | — | 0.0019 |
Returns & Leverage Ratios (%)
| Metric (%) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Company-reported ROCE (%) | -15 | -28 | -10 | -14 | -10 |
Country (% of FY2026 Shipment Quantity) Overview
| Country (% of FY2026 shipment quantity) | FY2026 |
|---|---|
South Korea | 47.7 |
Japan | 28.6 |
United States | 10.9 |
Germany | 5.3 |
Hong Kong | 5.3 |
China | 1.2 |
Spain | 0.8 |
Australia | 0.2 |
Regional Grouping Details
| Regional grouping (% of FY2026 shipment quantity, derived) | FY2026 |
|---|---|
North Asia (Korea, Japan, Hong Kong, China) | 82.8 |
Americas (United States) | 10.9 |
Europe (Germany, Spain) | 6.1 |
Australia | 0.2 |
Platform Details — HPA First — semiconductor
| Platform | Korea | Japan | US | Europe | China / HK | Australia |
|---|---|---|---|---|---|---|
HPA First — semiconductor (gamma alumina, GAP-X, ATH) | Primary | Primary | Emerging (equipment, CMP) | — | — | — |
HPA First — chemicals / Al-nitrate | — | — | Yes (CMP, coatings, medical lasers) | Yes (aerospace coatings) | — | — |
HPA First — LED | — | — | — | Germany | — | — |
HPA First — catalysts | — | — | Yes (20 t open order) | — | — | — |
HPA First — pharmaceutical | Yes | — | — | — | — | — |
Alpha Sapphire | — | — | — | Austria (wafers) | Boules, tablets | — |
Research / aerospace | — | — | Yes | — | — | Yes |
Per-Share Data
| Metric (A$ per share) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|
Fiscal year-end share price (derived) | 0.71 | 0.57 | 1.165 | 0.88 | 0.87 | 0.665 |
Annual change in share price (reported) | — | -0.140 | 0.595 | -0.285 | -0.010 | -0.205 |
Return measure (to 30 June 2026, price only) | Value (%) | — | — | — | — | — |
1-year (FY2026) | -23.6 | — | — | — | — | — |
3-year (from 30 Jun 2023) | -42.9 | — | — | — | — | — |
5-year (from 30 Jun 2021) | -6.3 | — | — | — | — | — |
Valuation Snapshot
| Multiple | Value | Comment |
|---|---|---|
Market capitalisation (AUD Mn) | ~965 | Derived |
Enterprise value (AUD Mn) | ~826 | Market cap less net cash of A$138.9m |
P/E | n/m | Loss-making |
EV/EBITDA | n/m | Negative EBITDA |
EV/Sales (x) | ~1,100 | Not meaningful as a valuation anchor |
P/B (x) | ~2.35 | Book value ~A$0.283/share |
EV / Stage Two budget (x) | ~1.18 | EV vs A$699.2m capex — an asset-based cross-check |
Capital Markets
| Item | Status |
|---|---|
Dividend history | Nil in every year FY2022–FY2026 |
Dividend policy | No dividends recommended; none expected pre-production |
Credit ratings (Moody's / S&P / Fitch) | None — company is unrated |
Debt Facilities
| Facility | Amount (AUD Mn) | Drawn at 30 Jun 2026 (AUD Mn) | Tenor / maturity |
|---|---|---|---|
NAIF/EFA Construction Facility | 320 | 0 | 11 years from Financial Close |
NAIF/EFA Cost Overrun Facility | 80 | 0 | 5 years from Financial Close |
QIC royalty investment | 30 | 30 | Royalty-based; carried at A$25.9m |
Lease liabilities | 2.4 | 2.4 | Short-dated |
Analyst Conclusions
Management guidance
No financial guidance. Operational guidance: Stage One upgrades complete October 2026; spray drying doubled by December 2026; NAIF/EFA first draw Q4 CY2026; major procurement complete by Q1 2027; balance of SMP and E&I contracts awarded in H2 CY2026; Stage Two first production late 2027 (some media cite completion late 2027 to early 2028); Al-nitrate supply to US Tier-1 CMP formulator from late CY2026; Stage Three concept studies ongoing.
Consensus growth expectations
Not publicly disclosed. Directionally, broker models imply revenue remaining sub-A$2m through FY2027 before stepping up with Stage Two ramp in FY2028.
Bull case
-
Unique low-alpha moat meets an AI demand super-cycle. If the <1 ppb U/Th specification is genuinely unmatched at scale, Alpha sits in a price-insensitive, qualification-gated niche of AI packaging and HBM; LOIs already exceed nameplate (12,000 tpa vs 10,430 tpa) and the demand model points to 50,000 tpa by 2030.
-
Fully funded on paper with sovereign anchors. ~A$167m liquid funds, A$400m undrawn senior debt (incl. A$80m overrun facility) and government equity create a deep-pocketed, policy-aligned shareholder base that lowers the probability of distressed funding.
-
Mix and capacity upside. Stage One "as-built" outperformance supports a 12,230 tpa upside scenario and a mix tilt toward higher-value semiconductor products than the 2024 DFS assumed, plus Stage Three optionality.
Bear case
-
Execution and cost risk on a 25–30x scale-up. A 26% re-baseline has already occurred before mechanical completion; SMP and E&I — historically the riskiest packages — were still being tendered in mid-2026.
-
Financing conditionality and thin headroom. Financial Close has lagged Contractual Close by ~22 months; funding lines of ~A$704m roughly equal the A$699.2m budget, leaving little buffer before more equity is needed at depressed prices.
-
Commercial conversion risk. LOIs are non-binding; achieved Stage One pricing (~US$26/kg) must hold at 10,000 tpa volumes, and incumbents may defend share; no binding Stage Two offtake was disclosed at 30 June 2026.
Key catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Expected timing | Why it matters |
|---|---|---|
| NAIF/EFA Financial Close and first draw | Q4 CY2026 | Unlocks A$400m; removes the largest funding uncertainty |
| September 2026 quarterly report | By 31 Oct 2026 | Capex run-rate, cash, contract progress |
| 2026 AGM | Q4 CY2026 (date not confirmed) | Remuneration votes; strategy update |
| Conversion of LOIs into binding Stage One CY2027 and Stage Two contracts | H2 CY2026–2027 | Validates revenue and pricing |
| Stage One upgrade completion | Oct–Dec 2026 | Revenue step-up in FY2027 |
| SMP/E&I contract awards vs budget | H2 CY2026 | Tests the A$699.2m re-baseline |
| CMP Al-nitrate first commercial supply (US Tier-1) | Late CY2026 | First scaled semiconductor chemical sale |
| Korean thermal filler qualification (1,200 tpa program) | 2026–2027 | Largest single semiconductor volume opportunity |
| Half-year FY2027 results | Feb 2027 | Burn, balance sheet |
| Stage Three concept-study outputs | 2,027 | Growth optionality |
Concluding analyst verdict
Alpha HPA is a high-conviction, high-variance industrial scale-up whose equity is effectively an option on two binary events: delivering a A$699 million plant to schedule in Gladstone, and converting a demonstrably large, AI-driven demand signal into binding, well-priced contracts. FY2026 materially de-risked the first event's funding dimension — A$225 million of new equity, a sovereign cornerstone in the NRFC, a fully drawn QIC instrument and ~A$167 million of liquid funds with no drawn bank debt — and maintained strong construction safety and procurement momentum. The commercial evidence also improved meaningfully: Stage One is sold out roughly threefold, LOIs exceed nameplate capacity, and the customer mix has rotated toward Japanese and Korean semiconductor packaging and US CMP formulators, where Alpha's ultra-low-alpha specification appears genuinely differentiated.
Against this, the record contains the warning signs typical of first-of-a-kind process plants: a 26% capex re-baseline, a long gap between Contractual and Financial Close on the senior debt, losses widening for a fifth consecutive year, and revenues that remain immaterial (A$0.75 million). Funding headroom over the re-baselined budget is slim, which makes the A$80 million cost-overrun facility a working part of the plan rather than a contingency. Governance is adequate for a company of this size but not best-practice: a non-independent executive Chair with related-party services, director-linked advisory fees, and an STI outcome that looks generous relative to missed milestones. Disclosure slips in the Appendix 4E reinforce the need for scrutiny.
At roughly A$0.8–1.1 billion of market value — around 1.2x the Stage Two budget on an EV basis — the market is pricing meaningful, but not full, success. The investment case strengthens decisively if the NAIF/EFA facilities close and are drawn in Q4 CY2026 and if the first binding semiconductor offtakes are signed before mechanical completion; failure on either front would likely force dilutive capital at unattractive prices. Verdict: speculative, execution-gated; monitor Financial Close and offtake conversion as the gating catalysts.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Director since | Background (summary) | Committees | Other listed boards |
|---|---|---|---|---|---|
Norman Seckold | Chair (non-independent, executive consultancy arrangement) | 30 Nov 2009 | BEc (Sydney); 35+ years leading resource companies | — | Chair: Nickel Industries, Sky Metals, Fulcrum Lithium, Minerals Exploration |
Robert Williamson | Managing Director | 1 May 2023 (MD from 1 Feb 2025) | Mechanical engineer; 20+ years in industrial processing; previously VP & GM leading rebuild/commissioning of a 155 ktpa SX zinc refinery in the US; joined Alpha 2020 | Risk & Sustainability; Nomination | — |
Rimas Kairaitis | Executive Director & Chief Commercial Officer | 1 Nov 2017 (MD until 1 Feb 2025) | Geologist; 30+ years; founding MD/CEO of Aurelia Metals | Nomination | Sky Metals |
Dr Regan Crooks | Independent Non-Executive Director | 6 Sep 2022 | Chemical engineer; technology commercialisation; 7 years at Solvay leading R&D/commercialisation | Chair Audit; Remuneration; Risk & Sustainability | — |
Marghanita Johnson | Independent Non-Executive Director | 15 Jan 2024 | CEO, Australian Aluminium Council since 2019; previously Rio Tinto government engagement, climate and sustainability roles | Chair Risk & Sustainability; Audit; Nomination | — |
Annie Liu | Non-Executive Director | 14 Dec 2023 | Former Tesla strategic partnerships and global sourcing (battery, storage, solar); earlier Ford | Remuneration | — |
Anthony Sgro | Non-Executive Director | 1 Nov 2017 | Chemical engineer; co-founded Kelair Pumps (1979, sold 2004) | Chair Nomination and Remuneration; Audit | — |
Executive Leadership Team
| Name | Title | Appointed | Background |
|---|---|---|---|
Robert Williamson | Managing Director | 1 Feb 2025 | As above |
Rimas Kairaitis | Executive Director & CCO | 1 Feb 2025 (CCO) | As above |
Craig Jones | Chief Financial Officer | 8 Jan 2024 (per Directors' Report; remuneration footnote says 8 Jan 2025) | 25+ years banking/corporate finance; 18 years structured lending incl. ANZ; KPMG Corporate Finance; previously advised Alpha on HPA First financing |
Peter Ware | Chief Operating Officer | 22 Sep 2025 | 25+ years chemical manufacturing, mining, major hazard facilities in Australia and South Africa; previously VP (Operations / Australian Manufacturing) at Incitec Pivot |
Richard Edwards | Company Secretary | 3 Sep 2012 | UNSW commerce; FGIA; CPA; also company secretary of Nickel Industries and European Resources |
Robert Lord | Investor Relations | — | Named IR contact (Jul 2026 quarterly) |
Directors' Remuneration
| KMP | Salary & fees | Other benefits | Superannuation | Share-based payments | Total | % performance-related |
|---|---|---|---|---|---|---|
Norman Seckold | 267,500 | 0 | 0 | 97,426 | 364,926 | 21.0 |
Robert Williamson | 541,300 | 45,415 | 64,956 | 229,550 | 881,221 | 19.5 |
Rimas Kairaitis | 470,628 | -10,938 | 56,475 | 225,439 | 741,604 | 20.3 |
Anthony Sgro | 103,341 | 0 | 12,401 | 0 | 115,742 | 0 |
Dr Regan Crooks | 115,500 | 0 | 0 | 0 | 115,500 | 0 |
Marghanita Johnson | 115,500 | 0 | 0 | 43,367 | 158,867 | 0 |
Annie Liu | 115,500 | 0 | 0 | 43,367 | 158,867 | 0 |
Craig Jones | 388,857 | 7,069 | 46,663 | 147,228 | 589,816 | 19.5 |
Peter Ware (from 22 Sep 2025) | 318,538 | 24,502 | 38,225 | 63,777 | 445,042 | 6.5 |
Total | 2,436,664 | 66,048 | 218,720 | 850,154 | 3,571,586 | 15.2 |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
8 Jan 2024 | Craig Jones appointed CFO | Strengthen project-finance capability ahead of debt process |
1 Feb 2025 | Rob Williamson becomes MD; Rimas Kairaitis moves to Executive Director & CCO; Peter Nightingale resigns as director | Transition from developer/commercial leadership to construction/operations leadership |
22 Sep 2025 | Peter Ware appointed COO | Major-hazard-facility operating experience ahead of Stage Two commissioning |
Major Shareholders
| Holder | Shares | Approx. % | Date / basis | Source |
|---|---|---|---|---|
Macquarie Group Ltd and controlled entities | 100,041,008 | 6.89 | 31 Jul 2026 (down from 8.23%) | Form 604 via Kalkine, 5 Aug 2026 |
National Reconstruction Fund Corporation | ~100,000,000 (A$75m at A$0.75) | ~6.9 (pro-forma) | Jan–Mar 2026 placement | Kalkine 30 Jan 2026 |
Norman Seckold (indirect, incl. pre-emptive right over 13.5m shares) | 50,949,166 | ~3.5 | 31 Aug 2026 | FY2026 Annual Report |
AustralianSuper | — | Substantial (>5%) per company | Jan 2026 | Placement announcement |
Orica Limited | — | Substantial per company | Jan 2026 | Placement announcement |
Regal Partners Ltd | — | Previously substantial | Apr 2025 | Simply Wall St insider log |
Rimas Kairaitis | 15,055,922 | ~1.0 | 31 Aug 2026 | FY2026 Annual Report |
Anthony Sgro | 5,500,752 | ~0.4 | 31 Aug 2026 | FY2026 Annual Report |
Robert Williamson | 1,812,807 | ~0.1 | 31 Aug 2026 | FY2026 Annual Report |
Competitive Landscape
Market Share by Competitor
| Competitor | Country | Segment overlap | Route / positioning | HPA-level revenue / share |
|---|---|---|---|---|
Sumitomo Chemical | Japan | HPA (alpha alumina), fillers | Incumbent premium supplier; alkoxide route | Not disclosed at HPA level |
Baikowski | France | HPA, CMP, LED, sapphire | Specialty alumina powders | — |
Sasol (Ceralox / high-purity alumina) | Germany / South Africa | HPA, boehmite, catalysts | Alkoxide-based high-purity aluminas | Not disclosed at HPA level |
Nippon Light Metal | Japan | High-purity alumina / hydroxide | Integrated aluminium chemicals | Not disclosed at HPA level |
Chinese HPA producers (e.g., Hebei Pengda and peers) | China | 4N–5N HPA, sapphire feedstock | Low-cost scale | — |
Spherical alumina filler makers (e.g., Denka, Admatechs, Resonac) | Japan | Thermal fillers | Potential customers and competitors in downstream fillers | Not disclosed at product level |
Altech Batteries (ASX: ATC) | Australia / Germany | HPA coatings (battery) | Kaolin-based HPA; pivoted toward battery products | — |
Cadoux (formerly FYI Resources) | Australia | HPA | Kaolin-based HPA; A$3m WA grant for small plant | — |
Andromeda Metals / Impact Minerals and other ASX juniors | Australia | HPA | Kaolin or alternative feeds; development stage | Pre-revenue |
Monocrystal and Chinese sapphire growers | Russia / China | Synthetic sapphire | Low-cost scale | — |
“—” = not publicly disclosed.
Peer Comparison FY2026
| Metric | Alpha HPA (FY2026) | Sumitomo Chemical | Baikowski | Sasol (HPA business) |
|---|---|---|---|---|
Revenue relevant to HPA | A$0.75m | Not disclosed at HPA level | — | Not disclosed at HPA level |
Revenue growth | +135% | — | — | — |
Margins | n/m (pre-production) | — | — | — |
R&D intensity | ~534% of sales (cash R&D) | — | — | — |
Route | Smart SX (nitric acid, solvent extraction) | Metal/alkoxide | Alum/other | Alkoxide |
Ultra-low-alpha (U/Th <1 ppb) | Claimed unique | Not claimed in retrieved sources | Not claimed | Not claimed |
“—” = not publicly disclosed.



